Prof Paul Gately, a specialist in childhood obesity at Leeds Metropolitan University, said a tool like this would help the NHS targetspecific people at risk rather than the "scattergun one-size-fits-all approach, which we know does not work".
The new drugs target very specific subsets of patients with the disease and will come with gene tests to pluck out which patients are likely to respond.